Accessibility Menu
Genmab A/s logo

Genmab A/s(NASDAQ) GMAB

Market Cap$19.07BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)+791%
5 Year-31%
1 Year+39%
1 Month+10%
$31.89
+1.74%
+0.55Today
After hours$32.00+$0.12 (+0.36%)
Genmab A/s last closing stock price
MetricPriceDate
Last closeUSD 31.942026-08-14
Genmab A/s stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.21%USD 31.252026-08-07
1 month+9.83%USD 29.082026-07-15
3 month+20.35%USD 26.542026-05-15
Year to date+3.7%USD 30.802025-12-31
1 year+38.99%USD 22.982025-08-14
3 year-14.12%USD 37.192023-08-15
5 year-31.42%USD 46.572021-08-13
Since inception+791.43%USD 3.582013-06-03

Genmab A/s Financials at a Glance

Market Cap

$19.07BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$4.13B

Net Income (TTM)

$788.10M

EPS (TTM)

$1.26

P/E Ratio

24.98

Dividend

$0.00

Beta (Volatility)

0.71 (Low)

Price

$31.89

Volume

3,427,175.428

Open

$31.31

Previous Close

$31.94

Daily Range

$31.14 - $31.98

52-Week Range

$23.22 - $35.43

Estimated Earnings Date

Nov 5, 2026

GMAB News

Person checking medicine on a shelf in a pharmacy

Why Genmab Stock Popped on Friday

Eric VolkmanOct 3, 2025
Person in a lab gazing into a microscope

Why Genmab Stock Was Marching Higher Today

Eric VolkmanSep 30, 2025
Person in a lab gazing into a microscope

Why Genmab Stock Smashed It on Monday

Eric VolkmanJun 2, 2025
DNA genetic sequencing biotech.jpg

Genmab Revenue Surges 18% in Q3

Motley Fool Markets TeamNov 6, 2024
cash-prescription-drugs-getty

AbbVie Signs $3.9 Billion Oncology Deal with Genmab

Cory RenauerJun 10, 2020
stock chart

Are There Good Investments Among 2019's Biotech IPOs?

David HaenOct 2, 2019

GMAB: Motley Fool Moneyball Superscore

68

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Genmab A/s

Genmab A/S is a biopharmaceutical company based in Copenhagen, Denmark, specializing in the discovery and development of innovative antibody therapies for cancer and other serious diseases. Founded in 1999, Genmab has established a strong portfolio of commercialized products and a robust pipeline of investigational medicines.

Products and Services
  • DARZALEX, a treatment for multiple myeloma and other blood cancers
  • Teprotumumab, indicated for thyroid eye disease
  • Amivantamab, targeting advanced gastric and non-small cell lung cancers
Growth Outlook
  • Recent quarterly revenue reached $899 million, indicating strong market demand
  • Pipeline includes multiple products in late-stage clinical trials, enhancing future revenue potential
  • Strategic collaborations with major pharmaceutical companies support ongoing research and development
Financial Highlights
  • Trailing twelve-month revenue of $3.9 billion reflects consistent growth
  • Net income for the latest quarter was $53 million, showcasing profitability
  • Current ratio of 2.18 indicates strong liquidity position
Genmab A/S has positioned itself as a leader in the biotechnology sector, focusing on innovative therapies that address unmet medical needs. The company's diverse product offerings and promising pipeline suggest a strong potential for future growth. Recent financial performance highlights, including substantial revenue and net income, further underscore the company's stability and market presence. With strategic partnerships and a commitment to research and development, Genmab is well-equipped to navigate the evolving landscape of the biopharmaceutical industry.
AI Generated • Jul 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3,119

CEO

Jan G. J. van de Winkel, PhD

Website

www.genmab.com

Headquarters

Copenhagen, CD 2500, DK

GMAB Financials

Key Financial Metrics (TTM)

Gross Margin

39.92%

Operating Margin

13.81%

Net Income Margin

8.17%

Return on Equity

13.58%

Return on Capital

11.11%

Return on Assets

6.30%

Earnings Yield

4.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$19.07BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

597.02M

Volume

3.43M

Avg. Volume

2.07M

Financials (TTM)

Gross Profit

$3.84B

Operating Income

$1.33B

EBITDA

$1.22B

Operating Cash Flow

$890.35M

Capital Expenditure

-$23.00M

Free Cash Flow

$867.34M

Cash & ST Invst.

$1.50B

Total Debt

$5.27B

Genmab A/s Performance Analysis

Genmab A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,049,135,24452.0%
20232023-12-31USD 2,390,322,51516.7%
20242024-12-31USD 3,121,756,72930.6%
20252025-12-31USD 3,731,385,66719.5%
Genmab A/s sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3010.5%
Q42025-12-313.2%
Q12026-03-31-14.7%
Q22026-06-3028.4%
Genmab A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 1.1761.2%
20232023-12-31USD 0.96-17.9%
20242024-12-31USD 1.7683.7%
20252025-12-31USD 1.54-12.5%
Genmab A/s sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3020.4%
Q42025-12-31-92.9%
Q12026-03-3180.4%
Q22026-06-30490.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.16B

+24.9%

Gross Profit

$1.07B

+23.4%

Gross Margin

92.73%

N/A

Market Cap

$19.07BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.18M

N/A

Employees

3,088

N/A

Net Income

$303.00M

-9.8%

EBITDA

$431.00M

-3.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.50B

-48.1%

Total Debt

$5.27B

+3463.6%

Accounts Receivable

$1.28B

+28.3%

Inventory

$18.00M

+38.5%

Long Term Debt

$4.96B

+3659.1%

Short Term Debt

$312.00M

+1850.4%

Return on Assets

6.30%

N/A

Return on Invested Capital

11.71%

N/A

Free Cash Flow

$48.00M

-7.7%

Operating Cash Flow

$51.00M

-17.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ZBHZimmer Biomet Holdings, Inc.
$100.65+1.08%
UTHRUnited Therapeutics Corporation
$499.73-0.31%
THCTenet Healthcare Corporation
$267.90+0.32%
INCYIncyte Corporation
$120.16-0.30%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About GMAB

What is the current price of Genmab A/s?

Genmab A/s is trading at $31.94 per share.

What is the 52-week range for Genmab A/s?

Over the past 52 weeks, Genmab A/s has traded between $23.22 and $35.43.

How much debt does Genmab A/s have?

As of the most recent reporting period, Genmab A/s reported total debt of $5.27B.

How much cash does Genmab A/s have on hand?

Genmab A/s reported $1.50B in cash and cash equivalents in its most recent financial results.

What is Genmab A/s’s dividend yield?

Genmab A/s does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services